CRISPR Therapeutics AG 8-K

What Happened CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2026 and provided other business highlights in a press release dated May 4, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8‑K (filed May 4, 2026). The Form 8‑K reports these results under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Announcement date: May 4, 2026; quarter covered: ended March 31, 2026.
• The company furnished a press release as Exhibit 99.1 (not "filed" for Section 18 liability purposes).
• The Form 8‑K was signed by Samarth Kulkarni, Ph.D., Chief Executive Officer.
• Information in the Form 8‑K (including Exhibit 99.1) is furnished, not filed, and therefore not subject to certain Exchange Act liabilities or automatically incorporated by reference in other filings.

Why It Matters This filing signals CRISPR Therapeutics has released its quarterly earnings and operational update; investors should review the furnished press release for the company’s reported revenue, earnings (or losses), clinical or program updates, and guidance. Note that because the release is furnished rather than filed, it carries different legal-status implications under the Exchange Act. For investment decisions, refer to the full press release and any subsequent filings (e.g., 10‑Q) for audited figures and additional disclosures.